DK3383397T3 - Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin - Google Patents
Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin Download PDFInfo
- Publication number
- DK3383397T3 DK3383397T3 DK16871332.9T DK16871332T DK3383397T3 DK 3383397 T3 DK3383397 T3 DK 3383397T3 DK 16871332 T DK16871332 T DK 16871332T DK 3383397 T3 DK3383397 T3 DK 3383397T3
- Authority
- DK
- Denmark
- Prior art keywords
- tenofovirdisoproxilfumarat
- doravirin
- lamivudin
- pharmaceutical compositions
- compositions containing
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biophysics (AREA)
- Communicable Diseases (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562261953P | 2015-12-02 | 2015-12-02 | |
| PCT/US2016/063894 WO2017095761A1 (en) | 2015-12-02 | 2016-11-29 | Pharmaceutical compositions containing doravirine, tenofovir disoproxil fumarate and lamivudine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3383397T3 true DK3383397T3 (da) | 2021-11-08 |
Family
ID=58797976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK16871332.9T DK3383397T3 (da) | 2015-12-02 | 2016-11-29 | Farmaceutiske sammensætninger indeholdende doravirin, tenofovirdisoproxilfumarat og lamivudin |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10603282B2 (da) |
| EP (3) | EP4424373B1 (da) |
| JP (1) | JP6866374B2 (da) |
| KR (1) | KR102774942B1 (da) |
| CN (1) | CN108367008B (da) |
| AU (1) | AU2016361612B2 (da) |
| BR (1) | BR112018011085B1 (da) |
| CA (1) | CA3006192C (da) |
| CY (1) | CY1124748T1 (da) |
| DK (1) | DK3383397T3 (da) |
| ES (1) | ES2895951T3 (da) |
| HR (1) | HRP20211687T1 (da) |
| HU (1) | HUE056978T2 (da) |
| LT (1) | LT3383397T (da) |
| MX (1) | MX374931B (da) |
| PL (1) | PL3383397T3 (da) |
| PT (1) | PT3383397T (da) |
| RS (1) | RS62466B1 (da) |
| RU (1) | RU2736941C2 (da) |
| SI (1) | SI3383397T1 (da) |
| WO (1) | WO2017095761A1 (da) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2736941C2 (ru) * | 2015-12-02 | 2020-11-23 | Мерк Шарп энд Доум Корп. | Фармацевтические композиции, содержащие доравирин, тенофовира дизопроксила фумарат и ламивудин |
| JP2020517633A (ja) * | 2017-04-18 | 2020-06-18 | シプラ・リミテッド | レトロウイルス感染の治療に用いる併用療法 |
| KR20260007293A (ko) * | 2018-02-02 | 2026-01-13 | 제넨테크, 인크. | 약제학적 화합물, 이의 염, 이의 제형, 그리고 이의 제조 방법 및 사용 방법 |
| CN113288905A (zh) * | 2021-07-14 | 2021-08-24 | 石家庄龙泽制药股份有限公司 | 含多替拉韦钠、拉米夫定和富马酸诺福韦酯的药物组合物 |
| CN115554248B (zh) * | 2022-08-25 | 2023-09-22 | 平阳润德医院有限公司 | 一种治疗小儿巨细胞病毒感染性肝炎的肠溶型中药制剂及其制备方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5047407A (en) | 1989-02-08 | 1991-09-10 | Iaf Biochem International, Inc. | 2-substituted-5-substituted-1,3-oxathiolanes with antiviral properties |
| US5922695A (en) | 1996-07-26 | 1999-07-13 | Gilead Sciences, Inc. | Antiviral phosphonomethyoxy nucleotide analogs having increased oral bioavarilability |
| US20080317852A1 (en) | 2005-12-14 | 2008-12-25 | Amar Lulla | Pharmaceutical Combination |
| WO2008156632A1 (en) * | 2007-06-12 | 2008-12-24 | Concert Pharmaceuticals, Inc. | Azapeptide derivatives |
| WO2009106960A2 (en) * | 2008-02-27 | 2009-09-03 | Aurobindo Pharma Limited | Stable compositions of lamivudine, tenofovir and efavirenz |
| EP2295038B1 (en) | 2009-09-11 | 2013-05-29 | AiCuris GmbH & Co. KG | Solid dispersion comprising an anti-HIV agent |
| CN102971308B (zh) | 2010-03-30 | 2015-02-04 | 默克加拿大有限公司 | 非核苷类逆转录酶抑制剂 |
| EP2714045A1 (en) | 2011-05-30 | 2014-04-09 | Cipla Limited | Pharmaceutical antiretroviral composition |
| EP2958563A2 (en) * | 2013-02-20 | 2015-12-30 | AbbVie Inc. | Tablet dosage form comprising ritonavir and lopinavir |
| MX375870B (es) | 2013-11-22 | 2025-03-07 | Merck Sharp & Dohme Llc | Composicion de un inhibidor de la transcriptasa inversa sin nucleosido. |
| WO2015179448A1 (en) * | 2014-05-21 | 2015-11-26 | Gilead Sciences, Inc. | Therapeutic compounds |
| RU2736941C2 (ru) * | 2015-12-02 | 2020-11-23 | Мерк Шарп энд Доум Корп. | Фармацевтические композиции, содержащие доравирин, тенофовира дизопроксила фумарат и ламивудин |
-
2016
- 2016-11-29 RU RU2018123620A patent/RU2736941C2/ru active
- 2016-11-29 RS RS20211287A patent/RS62466B1/sr unknown
- 2016-11-29 HR HRP20211687TT patent/HRP20211687T1/hr unknown
- 2016-11-29 AU AU2016361612A patent/AU2016361612B2/en active Active
- 2016-11-29 SI SI201631373T patent/SI3383397T1/sl unknown
- 2016-11-29 HU HUE16871332A patent/HUE056978T2/hu unknown
- 2016-11-29 MX MX2018006773A patent/MX374931B/es active IP Right Grant
- 2016-11-29 CA CA3006192A patent/CA3006192C/en active Active
- 2016-11-29 DK DK16871332.9T patent/DK3383397T3/da active
- 2016-11-29 BR BR112018011085-0A patent/BR112018011085B1/pt active IP Right Grant
- 2016-11-29 ES ES16871332T patent/ES2895951T3/es active Active
- 2016-11-29 PT PT168713329T patent/PT3383397T/pt unknown
- 2016-11-29 JP JP2018528299A patent/JP6866374B2/ja active Active
- 2016-11-29 PL PL16871332T patent/PL3383397T3/pl unknown
- 2016-11-29 EP EP24183101.5A patent/EP4424373B1/en active Active
- 2016-11-29 LT LTEPPCT/US2016/063894T patent/LT3383397T/lt unknown
- 2016-11-29 US US15/780,142 patent/US10603282B2/en active Active
- 2016-11-29 EP EP21197509.9A patent/EP3960163A1/en not_active Withdrawn
- 2016-11-29 KR KR1020187015257A patent/KR102774942B1/ko active Active
- 2016-11-29 EP EP16871332.9A patent/EP3383397B1/en active Active
- 2016-11-29 WO PCT/US2016/063894 patent/WO2017095761A1/en not_active Ceased
- 2016-11-29 CN CN201680070227.0A patent/CN108367008B/zh active Active
-
2020
- 2020-02-14 US US16/791,398 patent/US10842751B2/en active Active
-
2021
- 2021-11-19 CY CY20211101008T patent/CY1124748T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3495023T3 (da) | Semifluorerede forbindelser og sammensætninger deraf | |
| DK3676297T3 (da) | Forbindelser, sammensætninger og fremgangsmåder | |
| DK3357513T3 (da) | Farmaceutisk sammensætning og anvendelse deraf | |
| DK3347472T3 (da) | Sammensætninger som indeholder cyp76ad1- clade polypeptider og anvendelse heraf. | |
| HUE067016T2 (hu) | Önfeláldozó csoportokat tartalmazó konjugátumok és ezekkel kapcsolos eljárások | |
| DK3297605T3 (da) | Topiske, farmaceutiske sammesætninger | |
| DK3354282T3 (da) | Glycan-terapeutiske midler og relaterede fremgangsmåder deraf | |
| DK3529248T3 (da) | Farmaceutiske sammensætninger | |
| BR112016023628A2 (pt) | composições farmacêuticas. | |
| IL257531A (en) | Therapeutic combinations comprising anti-folr1 immunoconjugates | |
| DK3655038T3 (da) | Farmaceutisk sammensætning | |
| SI4070787T1 (sl) | Farmacevtske formulacije | |
| DK3233111T3 (da) | Farmaceutisk sammensætning, der omfatter plasminogen, og anvendelser deraf | |
| IL258160B (en) | Biaryl derivatives, pharmaceutical preparations containing them and their uses | |
| PL3310340T3 (pl) | Formulacje o wysokim stężeniu | |
| DK3236934T3 (da) | Farmaceutisk sammensætning, fremstilling og anvendelser deraf | |
| DK3223796T3 (da) | Farmaceutiske sammensætninger, fremstilling og anvendelser deraf | |
| DK3388085T3 (da) | Farmaceutisk sammensætning og anvendelser deraf | |
| DK3365321T3 (da) | Solabegron-zwitterion og anvendelser deraf | |
| DK3275454T3 (da) | Farmaceutisk sammensætning med silybin, ve og l-carnitin | |
| DK3583943T3 (da) | Farmaceutisk sammensætning | |
| DK3328368T3 (da) | Forbindelser og farmaceutisk sammensætning associeret med ubiquitinering-proteasomsystem | |
| DK3386956T3 (da) | Fumagillolderivater og polymorfer deraf | |
| DK3229843T3 (da) | Farmaceutisk sammensætning, præparat og anvendelser deraf | |
| DK3280447T3 (da) | Farmaceutiske formuleringer |